Fig. 11
From: Advances of nano drug delivery system for the theranostics of ischemic stroke
Schematic design and characterization of tP-NP-rtPA/ZL006e. A Main components of the tP-NP-rtPA/ZL006e. B After intravenous injection, tP-NP-rtPA/ZL006e was targeted to the thrombus for thrombin-triggered release of rtPA. C Nanocarrier transport into the brain via Tat-mediated transcytosis. D Cumulative release of rtPA from tP-NP-rtPA/ZL006e with different thrombin concentrations and nP-NP-rtPA/ZL006e in 1 U/mL thrombin. The reactions were performed in NaHCO3 (50 × 10− 3 M, pH 8.0) at 37 °C, with constant shaking. Error bars indicate standard deviation (n = 3). E Cumulative release of ZL006e from tP-NP-rtPA/ZL006e in phosphate-buffered saline with different pH levels at 37 °C, with constant shaking. Error bars indicate standard deviation (n = 3). F Representative TTC-stained brain sections of the MCAO model group, sham-operated group, tP-NP-rtPA/ZL006e group, nP-NP-rtPA/ZL006e group, and free ZL006e + rtPA group. The nonischemic area is observed as red, and the infarct area is shown in white. Reproduced with permission from [185]. Copyright 2019, American Chemical Society